PROFILPELAJAR.COM

Tarlatamab
Monoclonal antibody
Type	Bi-specific T-cell engager
Source	Human
Target	DLL3 and CD3
Clinical data
Trade names	Imdelltra
Other names	AMG757; AMG-757, tarlatamab-dlle
AHFS/Drugs.com	Multum Consumer Information
License data	US DailyMed: Tarlatamab;
Routes of; administration	Intravenous
Drug class	Antineoplastic
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	2307488-83-9;
DrugBank	DB17256;
UNII	74X82ST8Q1;
KEGG	D12234;
Chemical and physical data
Formula	C4664H7139N1259O1454S34
Molar mass	105202.82 g·mol−1

Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer.^[1] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3.^[1]

The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.^[2]

It was approved for medical use in the United States in May 2024.^[2]^[3]

Medical uses

Tarlatamab is indicated for the treatment of adults with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.^[1]^[2]

Adverse effects

The prescribing information for tarlatamab includes a boxed warning for serious or life-threatening cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS).^[1]

The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.^[2] The most common grade 3 or 4 laboratory abnormalities include decreased lymphocytes, decreased sodium, increased uric acid, decreased total neutrophils, decreased hemoglobin, increased activated partial thromboplastin time, and decreased potassium.^[2]

History

Efficacy was evaluated in 99 participants with relapsed/refractory extensive stage small cell lung cancer with disease progression following platinum-based chemotherapy enrolled in DeLLphi-301 [NCT05060016], an open-label, multicenter, multi-cohort study.^[2] Participants with symptomatic brain metastases, interstitial lung disease or non-infectious pneumonitis, and active immunodeficiency were excluded.^[2] Participants received tarlatamab until disease progression or unacceptable toxicity.^[2]

The FDA granted the application for tarlatamab priority review, breakthrough therapy, and orphan drug designations.^[2]

Society and culture

Names

Tarlatamab is the international nonproprietary name^[4] and the United States Adopted Name.^[5]

References

^ ^a ^b ^c ^d ^e "Imdelltra (AMG757)- tarlatamab-dlle kit". DailyMed. 16 May 2024. Retrieved 31 May 2024.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer". U.S. Food and Drug Administration (FDA). 16 May 2024. Retrieved 17 May 2024. This article incorporates text from this source, which is in the public domain.
^ "FDA approves Imdelltra (tarlatamab-dlle), the first and only T-cell engager therapy for the treatment of extensive-stage small cell lung cancer" (Press release). Amgen. 16 May 2024. Retrieved 18 May 2024 – via PR Newswire.
^ World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85". WHO Drug Information. 35 (1). hdl:10665/340684.
^ "Tarlatamab". AMA Finder. Retrieved 18 May 2024.

External links

"Tarlatamab". NCI Drug Dictionary.
"Tarlatamab (Code C175858)". NCI Thesaurus.
Clinical trial number NCT05060016 for "A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301)" at ClinicalTrials.gov